CYP19A1 and breast carcinoma: A recent study established a model depicting that long-term aromatase inhibitors (AI) treatment promotes constitutive activation of SREBP1, which leads to reactivation of ERα and cytoskeletal rearrangements via Keratin-80 and promotes the invasive phenotype of breast cancer cells [27].